If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAukett Swanke Regulatory News (AUK)

  • There is currently no data for AUK

Trading Update

4 Nov 2019 07:00

RNS Number : 0483S
Aukett Swanke Group PLC
04 November 2019
 

 

Aukett Swanke Group plc

Trading Update and update regarding Aukett Swanke Moscow

Aukett Swanke Group Plc (the group) ("ASG"), the international group of architects, interior designers and associated engineering is pleased to provide the following trading update on performance to 30 September 2019.

The Board expressed the view that second half trading would be profitable and that this should result in recovering the first half loss to show a positive result at the year end. The Board is now pleased to be able to confirm that this remains the case and that the Group will achieve a profit for the full year to 30 September 2019, subject to there being no material impact for IFRS 9 and 15. Full year results will be reported in January 2020.

At the same time the Board can confirm that year end cash stood at £1,145,000 (2018: £710,000) and after deducting the Long Term Loan used to acquire Shankland Cox, Net Funds stood at £819,000 (2018: £157,000); a satisfactory improvement.

Trading in the new financial year has been stable though we remain vigilant regarding possible adverse impacts as a result the forthcoming General Election and prolonged Brexit negotiations.

Since the year end we have also sold the Group's subsidiary in Moscow, Aukett Swanke OOO ("AS Moscow"), having previously stated the Board's belief that AS Moscow would perform better under local ownership. Under the terms of a Sale Agreement AS Moscow was sold to Maxim Neretin, a Russian national, owner of Aurora Group (another Moscow based architectural practice) with whom the Group has previously co-operated on design projects, for a nominal consideration. The sale will result in inter-company loans being repaid to the Group and, under the terms of a licence arrangement, enables AS Moscow to continue to trade as Aukett Swanke, allowing the Group's brand to endure in this important market. The sale also safeguards our staffs' employment and was achieved without any warranties being provided to the new owner. AS Moscow made a loss of £17,000 in the year to 30 September 2018.

Commenting Nicholas Thompson, CEO, said:

"The recovery from the large loss in 2018 is a tribute to the perseverance of the staff in all of our operations and in the internal rigours of reducing cost during a difficult trading period.

The process to find a suitable successor to carry on the Russian business in our name has taken some considerable time to realise. Critically, the sale has safeguarded the interests of our staff in Moscow, avoids a costly closure process and provides some upside for shareholders through the ongoing licence arrangement. We are pleased with the outcome".

Enquiries

Aukett Swanke group Plc 020 7843 3000

Nicholas Thompson, Chief Executive Officer

Robert Fry, MD International

Tony Barkwith, Group Finance Director

 

finnCap 020 7220 0500

Corporate Finance: Julian Blunt/Giles Rolls

ECM: Alice lane

 

Investor /Media Enquiries 07979 604687

Chris Steele

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTFSLFMFFUSELF
Date   Source Headline
8th Dec 202212:40 pmRNSBoard Changes
17th Nov 20229:00 amRNSHolding(s) in Company
5th Oct 20223:15 pmRNSHolding(s) in Company
6th Sep 20227:00 amRNSHolding(s) in Company
2nd Sep 202211:20 amRNSHolding(s) in Company
16th Aug 20227:00 amRNSHolding(s) in Company
4th Aug 20223:27 pmRNSHolding(s) in Company
4th Aug 20223:24 pmRNSHolding(s) in Company
25th Jul 202210:53 amRNSCompletion of Nominated Adviser Due Diligence
29th Jun 20227:00 amRNSInterim Results
7th Jun 20226:00 pmRNSHolding(s) in Company
29th Apr 20227:00 amRNSSale of John R Harris & Partners Limited
29th Apr 20227:00 amRNSSale of John R Harris & Partners Limited
28th Apr 20227:00 amRNSAppointment of Nominated Adviser
26th Apr 20227:00 amRNSAnnouncement of results of AGM
11th Apr 20227:00 amRNSHolding(s) in Company
31st Mar 20227:00 amRNSAnnouncement of final results for the year end
28th Feb 20228:45 amRNSHolding(s) in Company
30th Jun 20217:00 amRNSGrant of Options to a director
29th Jun 20217:00 amRNSInterim results
29th Mar 20212:47 pmRNSResult of AGM
4th Mar 20217:00 amRNSNotice of AGM, Annual Report and Accounts
18th Feb 20217:00 amRNSAnnouncement of final audited results
1st Feb 20217:00 amRNSBuilding Design Survey Ranking
9th Nov 20207:45 amRNSTrading Statement
2nd Nov 20208:00 amRNSAppointment of Nominated Adviser and Sole Broker
2nd Nov 20207:00 amRNSAIM Rule 17 Schedule 2(g) Update
14th Oct 20205:15 pmRNSHolding(s) in Company
24th Aug 20205:57 pmRNSGrant of Options to a Director
24th Jun 20207:00 amRNSInterim Results
26th Mar 20201:46 pmRNSResult of AGM
26th Mar 20207:00 amRNSAGM Statement
30th Jan 20207:00 amRNSFinal Results
4th Nov 20197:00 amRNSTrading Update
29th Jul 20197:00 amRNSCity Heritage Award
9th Jul 20199:52 amRNSBoard change
28th Jun 20197:00 amRNSInterim Results
24th Jun 20192:14 pmRNSNotice of Interim Results
24th Jun 201910:49 amRNSSamanea Market Dubai
10th May 201912:06 pmRNSDirector Appointment
8th Apr 20197:00 amRNSTrading Update
28th Mar 201911:16 amRNSResult of AGM
28th Mar 20197:00 amRNSAGM Statement
25th Mar 20199:49 amRNSBoard changes
8th Mar 20192:45 pmRNSNotice of Annual General Meeting and Annual Report
5th Feb 20195:42 pmRNSDirectorate Change
30th Jan 20197:00 amRNSFinal Results
8th Jan 20197:00 amRNSNotice of Results
20th Dec 20182:15 pmRNSDirector/PDMR Shareholding
5th Oct 20187:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.